The Indian Pharmaceutical Market (IPM) clocked Rs 6636 crores in May 2014 and the market has seen a growth of 8.1 per cent in the same month. Hegde & Hegde has become the 50th biggest corporate in the IPM.
Amongst the top 10, Sun Pharma grew at 15.2 per cent followed by Mankind at 13.3 per cent and Lupin at 11.7 per cent. 29 corporates have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Akumentis has the highest growth of 54.1 per cent followed by Ajanta at 45 per cent and Biocon at 44.8 per cent.
Amongst the 11-20 ranked companies, Macleods has shown high growth at 26.7 per cent followed by Biocon at 44.8 per cent and Apex at 39.6 per cent. Amongst the 50-60 ranked corporates, Apex grows at 39.6 per cent followed by Troikaa at 30 per cent and Panacea at 25.2 per cent. Amongst the 61-75 ranked corporates, Corona grows at 41.1 per cent followed by Pharmed at 28.8 per cent and Serdia at 21.2 per cent.
Indian companies have grown at 10.5 per cent versus 1.8 per cent for MNCs in May 2014. Amongst the top 50 in MNCs MSD grew the highest at 20.9 per cent, followed by Merck at 13.9 per cent and Janssen at 8.1 per cent. Under the non-NLEM category Indian companies are growing at 10.4 per cent whereas MNCs are growing at 1.6 per cent.
With Bonus Units at Full Value | (Val in Crs) | |||||||
Val in Crs | Rank | MAT May-14 | May-14 | |||||
CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 76567 | 100.00 | 5.9 | 6636 | 100.00 | 8.1 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4893 | 6.39 | 3.8 | 414 | 6.44 | 4.8 |
| Sun Pharma | 2 | 2 | 4168 | 5.44 | 15.4 | 377 | 5.34 | 15.2 |
| Cipla | 3 | 3 | 3809 | 4.97 | 6.2 | 326 | 4.97 | 6.8 |
| Zydus + Biochem | 4 | 4 | 3363 | 4.39 | 6.3 | 281 | 4.39 | 4.3 |
| Ranbaxy | 5 | 6 | 2836 | 3.70 | – 3.6 | 233 | 3.98 | – 4.7 |
| Mankind | 6 | 5 | 2727 | 3.56 | 5.4 | 243 | 3.50 | 13.3 |
| Glaxo | 7 | 8 | 2710 | 3.54 | -15.6 | 227 | 4.02 | – 7.8 |
| Alkem + Cachet + Indchemie | 8 | 9 | 2673 | 3.49 | 9.9 | 226 | 3.39 | 8.3 |
| Lupin | 9 | 7 | 2581 | 3.37 | 11.7 | 230 | 3.36 | 11.7 |
| Pfizer | 10 | 11 | 2226 | 2.91 | 3.0 | 189 | 2.95 | 4.0 |
| Emcure + Zuventus | 11 | 12 | 2162 | 2.82 | 15.0 | 183 | 2.65 | 12.9 |
| Macleods | 12 | 10 | 2056 | 2.69 | 11.5 | 198 | 2.55 | 26.7 |
| Sanofi | 13 | 13 | 1926 | 2.52 | 0.3 | 175 | 2.65 | 7.7 |
| Intas | 14 | 14 | 1909 | 2.49 | 7.0 | 168 | 2.55 | 7.4 |
| Aristo | 15 | 15 | 1877 | 2.45 | 14.7 | 164 | 2.17 | 23.1 |
| Glenmark | 16 | 18 | 1667 | 2.18 | 15.7 | 131 | 1.89 | 13.6 |
| Dr. Reddys | 17 | 16 | 1635 | 2.14 | 5.7 | 144 | 2.16 | 8.9 |
| Micro + Bal | 18 | 17 | 1572 | 2.05 | 9.3 | 139 | 2.15 | 5.7 |
| USV | 19 | 21 | 1407 | 1.84 | 9.1 | 118 | 1.87 | 3.1 |
| Torrent | 20 | 19 | 1394 | 1.82 | 14.0 | 127 | 1.79 | 15.1 |
| IPCA | 21 | 20 | 1372 | 1.79 | 20.4 | 124 | 1.59 | 27.8 |
| Wockhardt | 22 | 22 | 1222 | 1.60 | 3.0 | 102 | 1.53 | 8.6 |
The DPCO 2013 containing molecules market was at –11.5 per cent whereas the non-DPCO market grew by eight per cent resulting in an overall growth of 5.2 per cent for May 2014. The DPCO 2013 portfolio for Pfizer degrew at 26.9 per cent, GSK degrew at 19.5 per cent and Ranbaxy degrew by 25 per cent.
From the therapy perspective, 11 therapies have outgrown the IPM growth and five therapies have double digit growths. The respiratory market grew at 11.8 per cent, gastrointestinal market grew at 7.2 per cent whereas the anti-infectives grew at 2.5 per cent. The anti-diabetic market grows at 17.2 per cent and cardiac at 7.8 per cent in chronic business. The derma market grew by 12.9 per cent.
From the regional perspective 13 regions have outgrown the IPM growth. Madhya Pradesh market grew the highest at 17.8 per cent followed by Vidarbha market at 15.3 per cent. No regions had negative growths in May 2014.
Glimepiride + Metformin becomes the number one market growing at 34.4 per cent, whereas Amoxycillin + Clavulanic Acid Market grows at 3.9 per cent. The markets of Vitamin-D grew by 34.7 per cent, Probiotic Microbes grew at 25.2 per cent, Levocetirizine + Montelukast by 24.4 per cent, Rosuvastain by 23 per cent, Levetiracetam by 22 per cent and Telmisartan by 19.4 per cent.
Val in Crs | MAT May 14 | Mnth MAY 14 | ||
Super Group | Val in Crs | GR% | Val in Crs | GR% |
| IPM | 76567 | 5.9 | 6636 | 8.1 |
| ANTI-INFECTIVES | 12593 | 0.0 | 1009 | 2.5 |
| CARDIAC | 9519 | 7.6 | 848 | 7.8 |
| GASTRO INTESTINAL | 8591 | 5.4 | 809 | 7.2 |
| VITAMINS / MINERALS / NUTRIENTS | 6846 | 5.3 | 615 | 9.0 |
| RESPIRATORY | 6043 | 10.3 | 437 | 11.8 |
| PAIN / ANALGESICS | 5501 | 3.9 | 481 | 8.5 |
| ANTI DIABETIC | 5499 | 15.2 | 514 | 17.2 |
| NEURO / CNS | 4772 | 5.8 | 417 | 5.7 |
| GYNAECOLOGICAL | 4745 | 1.6 | 424 | 5.5 |
| DERMA | 4377 | 11.7 | 375 | 12.9 |
| OPHTHAL / OTOLOGICALS | 1387 | 9.1 | 129 | 11.8 |
| HORMONES | 1296 | 3.7 | 112 | 9.2 |
| VACCINES | 1094 | – 3.6 | 88 | – 9.3 |
| ANTI-NEOPLASTICS | 1079 | 28.6 | 102 | 26.2 |
| BLOOD RELATED | 925 | 4.1 | 78 | 2.3 |
| OTHERS | 896 | 4.4 | 87 | 22.5 |
| ANTI MALARIALS | 628 | 2.7 | 43 | 14.8 |
| SEX STIMULANTS / REJUVENATORS | 429 | 3.3 | 36 | – 2.7 |
| STOMATOLOGICALS | 346 | 9.1 | 32 | 15.5 |
Lantus grows at 26.1 per cent amongst the top 10 brands and adds up nine ranks to be the seventh biggest brand in the IPM for the month of May 2014.
Amongst the brands who have gained ranks include Glycomet-GP (+7), Liv-52 (+7), Skinlite (+10), Zincovit, Galvus Met (+21), Gluconorm-G (+39), Jalra-M (+51), Telma (+16), Orofer – XT (+13), Susten (+32), Pan-D (+10), Dolo (+44), Zerodol-P (+66), Dynapar AQ (+90) amongst top 100 Brands.
Amongst the top brands in the IPM, Glycomet GP (23.7 per cent), Lantus (26.1 per cent), Galvus Met (45.1 per cent), Skinlite (24.1 per cent), Telma (22.4 per cent), Zincovit (32 per cent) Liv-52 (17 per cent) grew fastest amongst top 25 Brands over May-13.
A total of 160 brands were launched in May 2014. MY HMG, HYLASTO ONE, LUMIA were the top NIs.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
